Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,183 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Upper Limb Clear all
Completed Phase 2 Interventional Results available

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

NCT02159365
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
29
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 19, 2026, 8:30 PM EDT
Recruiting Phase 3 Interventional

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT07059000
View directory record Official record
Conditions
Chronic Primary Immune Thrombocytopenia (ITP)
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Shirley, New York • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 8:30 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

NCT07348692
View directory record Official record
Conditions
Pneumococcal Immunization, Healthy Volunteers
Interventions
PCV21 vaccine, 20vPCV licensed vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
14
States / cities
Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Phase 3 Interventional Results available

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

NCT05295732
View directory record Official record
Conditions
Ichthyosis
Interventions
TMB-001, Matching Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
6 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Palo Alto, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02850965
View directory record Official record
Conditions
Psoriasis
Interventions
BI 695501, Humira
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 19, 2026, 8:30 PM EDT
Not yet recruiting Phase 2 Interventional

Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers

NCT07723534
View directory record Official record
Conditions
Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Interventions
Zolbetuximab, mFOLFOX6, CAPOX
Drug
Lead sponsor
Midhun Malla
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Not applicable Interventional

Fully Remote, Telehealth-based Ketogenic Metabolic Therapy for Long COVID

NCT07745699
View directory record Official record
Conditions
Long COVID Fatigue
Interventions
Ketogenic Metabolic Therapy, Lifestyle Intervention
Other · Behavioral
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Theta Burst Stimulation to Promote Motor Re-education in Tetraplegia

NCT03277521
View directory record Official record
Conditions
Quadriplegia/Tetraplegia
Interventions
Intermittent theta burst stimulation
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Phase 1 Interventional

A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period

NCT03414736
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR425899
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Not applicable Interventional Results available

Myoelectric Upper Limb Orthosis Use by Persons With TBI and Stroke

NCT03215771
View directory record Official record
Conditions
Traumatic Brain Injury, Stroke
Interventions
MyoPro Motion-G, Motor Learning-Based Therapy
Device · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Phase 4 Interventional

DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

NCT00116116
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
efavirenz, stavudine extended release, lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
10
States / cities
Bakersfield, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Not applicable Interventional

Arm Function and Quality of Life Following Mastectomy.

NCT00379106
View directory record Official record
Conditions
Breast Cancer
Interventions
Arm Exercises
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 19, 2026, 8:30 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Safety and Tolerability Study of OPF-110 in Healthy Adults

NCT07848334
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OPF-110, SMOFLIPID
Drug
Lead sponsor
Otsuka Pharmaceutical Factory, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 8:30 PM EDT
Active, not recruiting Not applicable Interventional

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

NCT06735534
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
FARAPULSE™ Pulsed Field Ablation System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 8:30 PM EDT
Completed No phase listed Observational

Comparing Wound Area Reduction of Non-healing DFUs Using MolecuLight i:X Versus Standard of Care

NCT04207099
View directory record Official record
Conditions
Non Healing Diabetic Foot Ulcer
Interventions
MolecuLight i:X Imaging Device
Device
Lead sponsor
MolecuLight Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Vista, California • Lake Success, New York • Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Strain Change Study for SARS-CoV-2 rS Vaccines

NCT06409663
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Interventions
NVX-CoV2705 Vaccine
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Phase 1 Interventional

Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

NCT01016730
View directory record Official record
Conditions
AIDS-Related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma
Interventions
Bortezomib, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Phase 3 Interventional

Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)

NCT00358228
View directory record Official record
Conditions
Smoking Cessation
Interventions
Rimonabant
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2010 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Renuvion Dermal System for Dermal Resurfacing

NCT04185909
View directory record Official record
Conditions
Wrinkle, Rhytides
Interventions
Renuvion Dermal System
Device
Lead sponsor
Apyx Medical
Industry
Eligibility
30 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Sherman Oaks, California • Jacksonville, Florida • Sarasota, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 19, 2026, 8:30 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

NCT06852963
View directory record Official record
Conditions
Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease, Eye Diseases Hereditary, Retinal Dystrophies
Interventions
VP-001
Drug
Lead sponsor
PYC Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 19, 2026, 8:30 PM EDT
Withdrawn Phase 2 Interventional

Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination

NCT00712621
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Counseling, Written materials
Behavioral
Lead sponsor
American Scitech International
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Englishtown, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 24, 2009 · Synced Oct 19, 2026, 8:30 PM EDT
Not listed Not applicable Interventional

Priming With tDCS: Expanding the Window of Recovery in Chronic Stroke

NCT03964467
View directory record Official record
Conditions
Upper Extremity Paresis
Interventions
transcranial direct current stimulation
Device
Lead sponsor
University of the Sciences in Philadelphia
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 19, 2026, 8:30 PM EDT
Completed Not applicable Interventional Results available

Study of Basivertebral Nerve Ablation Treatment of Chronic Low Back Pain

NCT03266107
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Intracept
Device
Lead sponsor
Relievant Medsystems, Inc.
Industry
Eligibility
25 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Carmel, Indiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 19, 2026, 8:30 PM EDT
Not listed Not applicable Interventional

Study of Nucel for One and Two Level Lumbar Interbody Fusion

NCT02808234
View directory record Official record
Conditions
Degenerative Disc Disease, Spondylolisthesis, Spondylosis
Interventions
One or two level lumbar interbody fusion surgery, Nucel
Procedure · Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Tampa, Florida • Shreveport, Louisiana • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 19, 2026, 8:30 PM EDT